Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.

BACKGROUND The aim of the study was to determine the outcome and clinical features predictive of survival in patients with follicular lymphoma (FL) treated aggressively and to determine the rate of disease-specific mortality in patients with grade 3 FL (FL3). MATERIALS AND METHODS Four hundred and twenty-one patients with FL who were treated with various anthracycline-based chemotherapy regimens were included in this retrospective study. RESULTS Patients with FL3 and a diffuse component of >50% had the worst outcome, with a hazard ratio of dying of 2.2 (95% CI 1.4-3.4) compared with patients with FL1 or FL2, and a ratio of 1.6 (95% CI 1.02-2.5) compared with FL3 with a diffuse component of < or =50% by multivariate analysis (P = 0.0026). Patients with FL3a had an outcome similar to those with FL3b. In patients with FL3 and a diffuse component of < or =50%, the overall and event-free survival curves showed a plateau for patients younger than 60 years of age. However, there were no differences in the cumulative incidence of relapse/progression or lymphoma-specific/treatment-related mortality between the two age groups. CONCLUSIONS Less than half of the patients with FL3 and a diffuse component of < or =50% treated with anthracycline-based combination chemotherapy will relapse and relapses are uncommon after 6 years. Older patients should be offered the same aggressive chemotherapy as younger patients.

[1]  R B Mann,et al.  Criteria for the cytologic subclassification of follicular lymphomas: A Proposed alternative method , 2007, Hematological oncology.

[2]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[3]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[4]  J. Armitage,et al.  Follicular lymphoma: expanding therapeutic options. , 2005, Oncology.

[5]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[6]  Robin L. Jones,et al.  Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? , 2003, British Journal of Cancer.

[7]  W. Chan,et al.  A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. , 2003, Blood.

[8]  T. Chisesi,et al.  The Role of Anthracyclines in Combination Chemotherapy for the Treatment of Follicular Lymphoma: Retrospective Study of the Intergruppo Italiano Linfomi on 761 Cases , 2003, Leukemia & lymphoma.

[9]  S. Cessie,et al.  Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  H. Kantarjian,et al.  Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Harris,et al.  The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 , 2000, Histopathology.

[12]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  P. Mclaughlin,et al.  Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. , 1999, Blood.

[14]  R. Fisher,et al.  Follicular lymphomas: do histologic subtypes predict outcome? , 1997, Hematology/oncology clinics of North America.

[15]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[16]  P. Gaulard,et al.  Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Ho,et al.  Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgkin's lymphomas , 1995 .

[18]  S. Proctor,et al.  Non-Hodgkin's Lymphomas , 1994, British Journal of Cancer.

[19]  S. Horning,et al.  Follicular large-cell lymphoma: intermediate or low grade? , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Chan,et al.  Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group. , 1994, Seminars in hematology.

[21]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[22]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[23]  J. Armitage,et al.  Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Longo,et al.  What's the deal with follicular lymphomas? , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Warnke,et al.  Clinical and pathologic features of follicular large cell (nodular histiocytic) lymphoma , 1987, Cancer.

[26]  P. Nichols,et al.  Large noncleaved follicular center cell lymphoma clinical features in 53 patients , 1986, Cancer.

[27]  H. Kantarjian,et al.  Follicular large cell lymphoma: analysis and prognostic factors in 62 patients. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Glick,et al.  Nodular histiocytic lymphoma: Factors influencing prognosis and implications for aggressive chemotherapy , 1982, Cancer.

[29]  L. Norton,et al.  Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. , 1980, Blood.

[30]  Z. Fuks,et al.  Non‐hodgkin's lymphomas iv. clinicopathologic correlation in 405 cases , 1973, Cancer.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  M. Mauch.  Non-Hodgkin's lymphomas , 2004 .

[33]  W. Bezwoda,et al.  Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group. , 1995, European Journal of Cancer.

[34]  C C Whitcomb,et al.  Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  National cancer institute sponsored study of classifications of non‐hodgkin's lymphomas. Summary and description of a working formulation for clinical usage , 2022 .